RATIONALE: Sputum biomarkers of infection and inflammation are noninvasive measures that enable quantification of the complex pathophysiology of cystic fibrosis (CF) lung disease. Validation of these biomarkers as correlates of disease severity is a key step for their application. OBJECTIVES: We constructed a large database from four multicenter studies to quantify the strength of association between expectorated sputum biomarkers and FEV(1.) METHODS: FEV(1) (range, 25-120% predicted) and quantitative data on expectorated sputum biomarkers including free neutrophil elastase, IL-8, neutrophils, Pseudomonas aeruginosa, and Staphylococcus aureus were obtained from 269 participants (ages, 9-54 years) from 33 centers. Cross-sectional and longitudinal statistical analyses were performed to estimate associations between the markers and FEV(1), including the use of multivariable analyses. RESULTS: Elastase was negatively correlated with FEV(1) (correlation [r] = -0.35; 95% confidence interval [CI]: -0.46, -0.22). On average, patients with CF who differed in their elastase measurements by 0.5 log differed in their FEV(1) values by -7.3% (95% CI: -9.7, -4.6). Neutrophil counts and IL-8 were also each negatively correlated. In a multivariable regression, elastase and neutrophil counts were able to explain the majority of variation in FEV(1). Elastase was further shown to have a significant longitudinal association with FEV(1), specifically a -2.9% decline in FEV(1) (95% CI: -5.0, -0.9) per 1-log increase in elastase. Although correlated with FEV(1), bacterial densities were unable to explain clinically meaningful differences in FEV(1) within and across patients. CONCLUSIONS: These data support the role of sputum biomarkers as correlates of disease severity in a diverse CF population.
RATIONALE: Sputum biomarkers of infection and inflammation are noninvasive measures that enable quantification of the complex pathophysiology of cystic fibrosis (CF) lung disease. Validation of these biomarkers as correlates of disease severity is a key step for their application. OBJECTIVES: We constructed a large database from four multicenter studies to quantify the strength of association between expectorated sputum biomarkers and FEV(1.) METHODS: FEV(1) (range, 25-120% predicted) and quantitative data on expectorated sputum biomarkers including free neutrophil elastase, IL-8, neutrophils, Pseudomonas aeruginosa, and Staphylococcus aureus were obtained from 269 participants (ages, 9-54 years) from 33 centers. Cross-sectional and longitudinal statistical analyses were performed to estimate associations between the markers and FEV(1), including the use of multivariable analyses. RESULTS: Elastase was negatively correlated with FEV(1) (correlation [r] = -0.35; 95% confidence interval [CI]: -0.46, -0.22). On average, patients with CF who differed in their elastase measurements by 0.5 log differed in their FEV(1) values by -7.3% (95% CI: -9.7, -4.6). Neutrophil counts and IL-8 were also each negatively correlated. In a multivariable regression, elastase and neutrophil counts were able to explain the majority of variation in FEV(1). Elastase was further shown to have a significant longitudinal association with FEV(1), specifically a -2.9% decline in FEV(1) (95% CI: -5.0, -0.9) per 1-log increase in elastase. Although correlated with FEV(1), bacterial densities were unable to explain clinically meaningful differences in FEV(1) within and across patients. CONCLUSIONS: These data support the role of sputum biomarkers as correlates of disease severity in a diverse CF population.
Authors: Scott D Sagel; Marci K Sontag; Jeffrey S Wagener; Robert K Kapsner; Iris Osberg; Frank J Accurso Journal: J Pediatr Date: 2002-12 Impact factor: 4.406
Authors: Claudia L Ordoñez; Noreen R Henig; Nicole Mayer-Hamblett; Frank J Accurso; Jane L Burns; James F Chmiel; Cori L Daines; Ronald L Gibson; Sharon McNamara; George Z Retsch-Bogart; Pamela L Zeitlin; Moira L Aitken Journal: Am J Respir Crit Care Med Date: 2003-09-11 Impact factor: 21.405
Authors: Nicole Mayer-Hamblett; Margaret Rosenfeld; Julia Emerson; Christopher H Goss; Moira L Aitken Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: Jacoba Johanna Louw; Jaan Toelen; Marijke Proesmans; François Vermeulen; Jaak Billen; Kris de Boeck Journal: Eur J Pediatr Date: 2011-06-01 Impact factor: 3.183
Authors: N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart Journal: J Cyst Fibros Date: 2020-06-07 Impact factor: 5.482
Authors: Kathryn L Griffin; Bernard M Fischer; Apparao B Kummarapurugu; Shuo Zheng; Thomas P Kennedy; Narayanam V Rao; W Michael Foster; Judith A Voynow Journal: Am J Respir Cell Mol Biol Date: 2014-04 Impact factor: 6.914
Authors: Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou Journal: Proc Am Thorac Soc Date: 2009-12
Authors: Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick Journal: Am J Respir Crit Care Med Date: 2012-08-16 Impact factor: 21.405